Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant
<b>Background:</b> B-cell depletion therapy was demonstrated to be a valid and safe alternative as an adjuvant in oral-pharyngeal pemphigus vulgaris (OPV) patients. We aimed to assess its effects on anti-desmoglein (Dsg) 1 and 3 and leukocytes subsets profile in these patients’ populatio...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/11/11/1634 |
| _version_ | 1797511056727212032 |
|---|---|
| author | Giulio Fortuna Elena Calabria Massimo Aria Amerigo Giudice Michele Davide Mignogna |
| author_facet | Giulio Fortuna Elena Calabria Massimo Aria Amerigo Giudice Michele Davide Mignogna |
| author_sort | Giulio Fortuna |
| collection | DOAJ |
| description | <b>Background:</b> B-cell depletion therapy was demonstrated to be a valid and safe alternative as an adjuvant in oral-pharyngeal pemphigus vulgaris (OPV) patients. We aimed to assess its effects on anti-desmoglein (Dsg) 1 and 3 and leukocytes subsets profile in these patients’ population. <b>Methods and Materials:</b> We evaluated the immunologic profile of 10 OPV patients treated with RTX as adjuvant by using the ELISA testing for anti-Dsg-1 and -3 titers and the immunophenotyping for B and T-cell lymphocyte subpopulations and compared them with the PDAI score for clinical remission. <b>Results:</b> A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (<i>p</i> < 0.001), in the CD8 (<i>p</i> = 0.009), and CD20 counts (<i>p</i> < 0.001). Multiple comparisons after Bonferroni adjustment confirmed such significant differences mainly between baseline and the end of RTX therapy and baseline and 6 months after RTX therapy. Only the anti-Dsg-3 titer at the end of RTX therapy demonstrated a slight positive correlation with the PDAI score at baseline (<i>p</i> = 0.046, <i>r =</i> 0.652). <b>Conclusions:</b> B-cell depletion adjuvant therapy in OPV patients demonstrated a significant impact on anti-Dsg-3 titer and B and T-cell lymphocyte subpopulations profile. |
| first_indexed | 2024-03-10T05:40:01Z |
| format | Article |
| id | doaj.art-25227ff5384d4019a68e59d6e2406d7f |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-10T05:40:01Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-25227ff5384d4019a68e59d6e2406d7f2023-11-22T22:34:04ZengMDPI AGBiomolecules2218-273X2021-11-011111163410.3390/biom11111634Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as AdjuvantGiulio Fortuna0Elena Calabria1Massimo Aria2Amerigo Giudice3Michele Davide Mignogna4Glasgow Dental School & Hospital, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G2 3JZ, UKDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, via Pansini 5, 80131 Naples, ItalyDepartment of Economics and Statistics, Federico II University of Naples, via Cinthia, Monte Sant’Angelo, 80126 Naples, ItalySchool of Dentistry, Department of Health Sciences, Magna Graecia University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Neurosciences, Reproductive Sciences and Dentistry, Federico II University of Naples, via Pansini 5, 80131 Naples, Italy<b>Background:</b> B-cell depletion therapy was demonstrated to be a valid and safe alternative as an adjuvant in oral-pharyngeal pemphigus vulgaris (OPV) patients. We aimed to assess its effects on anti-desmoglein (Dsg) 1 and 3 and leukocytes subsets profile in these patients’ population. <b>Methods and Materials:</b> We evaluated the immunologic profile of 10 OPV patients treated with RTX as adjuvant by using the ELISA testing for anti-Dsg-1 and -3 titers and the immunophenotyping for B and T-cell lymphocyte subpopulations and compared them with the PDAI score for clinical remission. <b>Results:</b> A significant difference in medians between baseline, end of RTX therapy, and 6 months after RTX therapy was observed in Dsg-3 titer (<i>p</i> < 0.001), in the CD8 (<i>p</i> = 0.009), and CD20 counts (<i>p</i> < 0.001). Multiple comparisons after Bonferroni adjustment confirmed such significant differences mainly between baseline and the end of RTX therapy and baseline and 6 months after RTX therapy. Only the anti-Dsg-3 titer at the end of RTX therapy demonstrated a slight positive correlation with the PDAI score at baseline (<i>p</i> = 0.046, <i>r =</i> 0.652). <b>Conclusions:</b> B-cell depletion adjuvant therapy in OPV patients demonstrated a significant impact on anti-Dsg-3 titer and B and T-cell lymphocyte subpopulations profile.https://www.mdpi.com/2218-273X/11/11/1634rituximabremissionoral pemphigus vulgarisdisease severityOPVdesmoglein |
| spellingShingle | Giulio Fortuna Elena Calabria Massimo Aria Amerigo Giudice Michele Davide Mignogna Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant Biomolecules rituximab remission oral pemphigus vulgaris disease severity OPV desmoglein |
| title | Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant |
| title_full | Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant |
| title_fullStr | Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant |
| title_full_unstemmed | Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant |
| title_short | Immunocytometric Analysis of Oral Pemphigus vulgaris Patients after Treatment with Rituximab as Adjuvant |
| title_sort | immunocytometric analysis of oral pemphigus vulgaris patients after treatment with rituximab as adjuvant |
| topic | rituximab remission oral pemphigus vulgaris disease severity OPV desmoglein |
| url | https://www.mdpi.com/2218-273X/11/11/1634 |
| work_keys_str_mv | AT giuliofortuna immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT elenacalabria immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT massimoaria immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT amerigogiudice immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant AT micheledavidemignogna immunocytometricanalysisoforalpemphigusvulgarispatientsaftertreatmentwithrituximabasadjuvant |